GLP-1 Drugs and Cancer: What the Evidence Says in 2026
Last reviewed: 19 October 2026. This article reviews the World Cancer Research Fund (WCRF) International position statement, GLP-1-related weight-loss medications and cancer, published in September 2026, alongside selected clinical research. The medical evidence is evolving; this page should be revisited as longer-term results become available.
GLP-1-related medicines have changed the treatment landscape for obesity and type 2 diabetes. Their growing use has raised an important question: Can these medicines prevent cancer, make cancer treatment more effective, or improve survival after a cancer diagnosis?
The current answer is cautious. These medicines can help eligible people lose weight and improve some aspects of metabolic health. Excess body fat is an established risk factor for several cancers. But it does not automatically follow that a weight-loss medicine has been proven to prevent cancer. Evidence about cancer incidence and outcomes after diagnosis remains incomplete, and observational associations cannot establish cause and effect.
What did WCRF International conclude?
In its September 2026 position statement, WCRF International describes the evidence linking GLP-1-related medicines with cancer prevention and survivorship as promising but inconclusive. The organisation emphasizes that excess body weight is associated with a higher risk of multiple cancers, while the long-term effects of these medicines on cancer risk and outcomes remain uncertain.
WCRF's main conclusion is that the evidence does not currently support using these medicines to prevent cancer or to improve cancer-treatment outcomes, quality of life, recurrence, or survival. It also stresses that medicines should complement—not replace—healthy eating, physical activity, and wider public-health policies that help people maintain health.
Read the original WCRF International position statement and its GLP-1 medicines and cancer explainer .
What are GLP-1-related medicines?
Glucagon-like peptide-1 (GLP-1) is a hormone released by the gut that helps regulate appetite and blood glucose. Medicines acting on this pathway can increase fullness, reduce appetite and food intake, and slow gastric emptying. They can support weight loss and glucose control when used for an approved indication alongside appropriate lifestyle and clinical support.
.png)
- Semaglutide and liraglutide act at the GLP-1 receptor.
- Tirzepatide activates both the GIP and GLP-1 receptors, so it is a dual agonist rather than a GLP-1-only drug.
Results for one medicine, formulation, dose, population, or duration should not automatically be assumed to apply to every drug in this broad group. Researchers are still working out whether any possible cancer-related effects differ between medicines or cancer types.
Why the cancer question matters
Excess body fatness is an established risk factor for several cancers. WCRF notes links with at least 13 cancer types, including colorectal, postmenopausal breast, endometrial, ovarian, pancreatic, liver, kidney, and oesophageal cancers. Research published in 2026 has discussed a wider set of cancer sites depending on the evidence threshold and definitions used; the exact count can therefore vary across reviews.
Body fatness can influence health through multiple pathways, including insulin resistance, chronic inflammation, sex-hormone signalling, and other metabolic changes. These mechanisms provide a rationale for studying weight-loss medicines in cancer prevention, but biological plausibility is not proof that a particular drug reduces cancer incidence in people.
Weight management is only one part of prevention. Avoiding tobacco, limiting alcohol, being physically active, eating a healthy dietary pattern, maintaining a healthy weight where feasible, and following recommended cancer screening remain important. No medication removes the need for age- and risk-appropriate screening.
What does the research show about cancer risk?
Different study designs answer different questions. Observational studies can identify associations in routine-care data, but users and non-users may differ in ways that are difficult to measure. Randomized trials are generally better for causal questions, yet most GLP-1 trials were designed to study diabetes, body weight, or cardiovascular outcomes—not cancer—and often did not follow participants long enough for cancer outcomes to be assessed reliably.
A 2026 meta-analysis of randomized trials
A systematic review and meta-analysis published in Annals of Internal Medicine in 2026 included 48 randomized trials with 94,245 participants. The authors concluded that GLP-1 receptor agonists probably have little or no effect on the risk of several obesity-related cancers based on currently available trial data. For several other cancers, the evidence was lower certainty; the effect on gastric cancer was very uncertain. Importantly, the included trials were not designed to assess cancer outcomes and had relatively short follow-up.
| Cancer outcome | Pooled estimate in the 2026 review | How to interpret it |
|---|---|---|
| Thyroid cancer | OR 1.37 (95% CI 0.82–2.31) | No statistically clear difference was demonstrated; the interval remains compatible with lower or higher risk. |
| Pancreatic cancer | OR 0.84 (95% CI 0.53–1.35) | No statistically clear reduction or increase was established. |
| Breast cancer | OR 0.95 (95% CI 0.60–1.49) | The pooled estimate does not establish a protective effect. |
| Kidney cancer | OR 1.12 (95% CI 0.78–1.60) | No statistically clear difference was demonstrated. |
OR = odds ratio; CI = confidence interval. These are relative estimates, not absolute individual probabilities. A result that is not statistically significant does not prove that a medicine has no effect; wide confidence intervals and rare events can leave meaningful uncertainty. See the full Ko et al. 2026 systematic review and meta-analysis .
Why have some observational studies looked more encouraging?
A 2025 retrospective cohort study using a target-trial-emulation approach compared 43,317 GLP-1 receptor agonist users with 43,315 matched non-users with obesity. It reported an association between GLP-1 receptor agonist use and lower overall incidence of the cancers studied (hazard ratio 0.83, 95% CI 0.76–0.91), with associations for some specific cancers as well. This is an interesting signal, but it is not proof that the medicines prevented cancer. Differences in health status, healthcare use, weight change, treatment selection, and other factors may still influence the results.
The 2024 study of people with type 2 diabetes and the subsequent observational literature add to the research question, but results vary by study population, comparator, drug exposure, and cancer type. The correct interpretation is not that cancer prevention has been demonstrated; it is that further, better-designed research is justified. See Dai et al. in JAMA Oncology (2025) and Wang et al. in JAMA Network Open (2024) .
Evidence snapshot
| Question | Evidence status | What we can responsibly say |
|---|---|---|
| Can GLP-1-related medicines help with weight loss? | Established for approved indications | Several medicines can produce clinically meaningful weight loss in eligible patients; individual response and tolerability vary. |
| Does weight loss necessarily mean lower cancer incidence from the medicine? | Not established | Weight and metabolic changes may matter, but drug-specific cancer prevention has not been demonstrated. |
| Do these medicines prevent cancer overall? | Unproven | Some observational studies report lower risks, but randomized-trial evidence does not establish a preventive effect. |
| Do they improve treatment response or prevent recurrence? | Insufficient evidence | These outcomes are being studied; GLP-1 medicines are not cancer treatments. |
| Is thyroid cancer risk fully settled? | No; uncertainty remains | Some labels carry a warning based on rodent findings. Human evidence has not conclusively settled the question. |
GLP-1 medicines and thyroid cancer: what should patients know?
Some medicines in this area have a warning about thyroid C-cell tumours, based mainly on findings in rodents. For example, the US prescribing information for semaglutide (Wegovy) states that it is unknown whether the rodent finding is relevant to humans. Under that US label, Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or with multiple endocrine neoplasia syndrome type 2 (MEN 2).
This warning is important, but it should not be simplified into the claim that these medicines are proven to cause thyroid cancer in humans. Equally, uncertainty should not be presented as proof of zero risk. Patients should review the exact medicine's current prescribing information in their country and disclose any relevant personal or family history to the prescriber. Routine calcitonin testing or thyroid ultrasound solely because a person takes semaglutide is not automatically warranted; the US label says the value of such routine monitoring is uncertain.
Read the US Wegovy prescribing information and consult local product information for the medicine actually being considered.
Related: GLP-1 Drugs and Cancer Risk: Do Ozempic, Wegovy and Zepbound Prevent or Cause Cancer?What about people living with or beyond cancer?
Some observational studies in people with breast, colorectal, or liver cancer have reported associations between GLP-1 receptor agonist use and selected outcomes, including survival or recurrence measures. Findings are not consistent across all outcomes, and observational designs cannot reliably show that the medicine caused the difference. Randomized trials have not yet established that GLP-1-related medicines improve cancer-treatment effectiveness, reduce recurrence or cancer-specific mortality, or improve quality of life.
A person with a cancer diagnosis may still have a valid reason to use a weight-management or diabetes medicine. But the risk-benefit assessment is more individualized during active treatment, recovery, or survivorship. The oncology team and prescribing clinician should consider cancer type and stage, current treatment, other medicines, weight trajectory, appetite, hydration, nutritional status, and the person's overall goals of care.
Why nutrition and muscle matter
Weight loss usually includes a mixture of fat mass and lean mass. Reduced appetite and gastrointestinal symptoms can make it harder for some people to eat enough. During cancer treatment, inadequate intake, involuntary weight loss, muscle loss, or frailty may undermine physical function and treatment tolerance. The risk is particularly relevant for patients already struggling with appetite, swallowing, nausea, bowel symptoms, or cancer-related wasting.
For people using a GLP-1-related medicine, an individualized plan may include adequate protein and overall energy intake, resistance exercise when medically appropriate, hydration, and monitoring of weight and physical function. People with cancer should get nutrition advice that reflects the cancer, treatment, symptoms, kidney function, and other clinical circumstances rather than following a generic high-protein or weight-loss plan. Do not pursue weight loss during active treatment without discussing the goal with the care team.
Possible biological mechanisms: plausible, but not proven
Researchers are investigating whether GLP-1-related medicines could affect cancer-related processes beyond the effect of weight loss. Proposed pathways include changes in insulin sensitivity, inflammation, hormone signalling, immune responses, and the tumour microenvironment. Laboratory and animal studies have reported effects on tumour growth or immune activity in selected experimental settings.
These findings can help researchers design human studies, but they should not be reported as clinical proof. Results from cells or animal models may not translate to people, and effects may differ by tumour biology, receptor expression, drug, dose, and clinical setting. At present, no general claim that GLP-1 medicines directly kill cancer cells or broadly suppress tumours is supported for patient care.
Clinical trials to watch
Research is moving beyond general weight loss to ask whether these medicines can be used safely and usefully in defined cancer settings. The WCRF statement lists several registered studies. Registration indicates that a study is planned or underway; it is not evidence that the medicine works. Trial status and posted results can change, so check the registry record before citing a study as active or completed.
| Study | Research question | Why it matters |
|---|---|---|
| FITWISE (NCT06518837) | Feasibility, safety and weight-loss intervention with tirzepatide during adjuvant treatment for early-stage hormone receptor-positive, HER2-negative breast cancer; includes exploratory measures such as circulating tumour DNA and quality of life. | Helps establish whether use during adjuvant treatment is feasible and what should be assessed in larger studies. It is not, by itself, proof of recurrence prevention. |
| NCT07314528 | A registered phase II study evaluating a GLP-1 receptor agonist alongside total neoadjuvant therapy for locally advanced rectal cancer. | Illustrates that researchers are beginning to test combination approaches and cancer-specific outcomes in clinical settings. |
| PROSPECT (NCT07095517) | A registered study examining pathways, risk factors, and molecules relevant to prevention of early-onset colorectal tumours. | May contribute to the wider prevention evidence base; its registration should not be interpreted as a demonstrated benefit of a GLP-1 medicine. |
Trial descriptions above are summaries of registry titles and the WCRF statement, not results. The registry should be consulted for the current study status, eligibility, interventions, and any posted findings.
What should patients do now?
If you are considering a medicine for obesity or type 2 diabetes
Discuss expected benefits, side effects, contraindications, cost, access, treatment duration, and the likelihood that ongoing treatment or a maintenance strategy may be needed. The decision should be based on an established clinical indication and personal circumstances—not on the promise that the medicine will prevent cancer.
If you have a history of cancer or are receiving treatment
Do not start, stop, or change a prescription solely because of a headline about cancer risk. Ask the oncology team and the clinician prescribing the medicine to review the reason for treatment, cancer-specific context, other medications, nutrition, muscle and bone health, side effects, and any potential effect on treatment scheduling or tolerance.
If your goal is cancer prevention
Focus on prevention measures with established evidence and follow screening guidance appropriate to age and risk. Healthy weight is one part of cancer prevention, but it is not the only part and cannot guarantee that cancer will not develop. GLP-1-related medicines should not replace a balanced diet, physical activity, tobacco avoidance, or recommended screening.
What research is still needed?
Several questions remain unresolved:
- How much of any association is explained by weight loss? Researchers need to distinguish the effects of weight change and improved metabolic health from any effects that might be independent of weight loss.
- Do effects differ by medicine or cancer type? Semaglutide, liraglutide, and tirzepatide have different pharmacology, and cancers differ in their biology. A single overall finding cannot answer every drug-cancer question.
- What happens over longer periods? Many cancers develop over years. Longer follow-up and studies designed around cancer incidence and cancer-specific outcomes are needed.
- What are the effects during cancer treatment? Researchers need to measure treatment tolerance and effectiveness, nutritional status, muscle and bone outcomes, physical function, quality of life, recurrence, and survival.
- Who can access treatment? Cost, coverage, availability, clinical support, and wider social conditions shape access. Medicines alone cannot address the social and environmental determinants of weight and cancer prevention.
Frequently asked questions
Do GLP-1 drugs prevent cancer?
Not on the evidence available as of October 2026. Some observational studies have reported lower cancer incidence, but randomized-trial evidence has not established that GLP-1-related medicines prevent cancer. They should not be prescribed solely for cancer prevention.
Do GLP-1 drugs cause cancer?
Current evidence does not establish that GLP-1 medicines broadly cause cancer in humans. However, no simple statement of zero risk is justified. Some medicines carry a thyroid C-cell tumour warning based mainly on rodent studies, and human data remain limited for rare cancers and long-term exposure. Follow the medicine's current prescribing information and discuss personal risk factors with a clinician.
Does semaglutide increase thyroid cancer risk?
The human evidence is not conclusive. The US Wegovy label warns about thyroid C-cell tumours observed in rodents and contraindicates use in people with a personal or family history of medullary thyroid carcinoma or MEN 2. This is a specific safety warning, not proof that semaglutide causes thyroid cancer in humans.
Can tirzepatide or semaglutide treat cancer?
No. They are not approved cancer treatments, and they should not replace surgery, radiotherapy, systemic therapy, or other care recommended by an oncology team. Research into possible roles alongside cancer care is ongoing.
Can a cancer survivor take a GLP-1 medicine?
A history of cancer does not by itself answer whether a particular person should or should not use one. The decision depends on the drug's indication and contraindications, cancer history, current treatment, nutritional status, other conditions, and the clinician's assessment. Coordinate the decision with both the prescribing clinician and oncology team when relevant.
Could weight loss from GLP-1 medicines be a problem during cancer treatment?
It can be for some people, particularly those with poor appetite, involuntary weight loss, malnutrition risk, or loss of muscle. Reduced food intake and gastrointestinal side effects may make nutritional goals harder to meet. Anyone undergoing treatment should discuss weight goals and symptom management with their care team.
Should GLP-1 medicines replace lifestyle changes for cancer prevention?
No. WCRF recommends that these medicines be considered, when clinically appropriate, as one part of a broader approach. Healthy eating, physical activity, and evidence-based prevention and screening remain important.
When will we know more?
More useful answers will come from longer-term follow-up, well-designed observational analyses, randomized studies with cancer-specific endpoints, and trials in clearly defined cancer populations. Trial registration alone does not mean a benefit has been proven.
Conclusion: promising research is not the same as proven cancer prevention
The September 2026 WCRF position statement provides a balanced reading of a fast-growing field. Excess body fat is an established cause of several cancers, and GLP-1-related medicines can help some people manage obesity and type 2 diabetes. But the evidence has not yet shown that these medicines prevent cancer or improve recurrence, treatment response, cancer-specific survival, or quality of life.
The practical approach is to use these medicines for established clinical indications, weigh risks and benefits individually, and be especially attentive to nutritional status and muscle preservation in people affected by cancer. Promising observational findings and laboratory mechanisms deserve further study—not stronger claims than the evidence can support.
Sources and further reading
- World Cancer Research Fund International. GLP-1-related weight-loss medications and cancer: Position statement. September 2026. Read statement and references .
- Ko A, et al. Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis. Annals of Internal Medicine. 2026;179(2):216–229. doi:10.7326/ANNALS-25-02237 .
- Dai H, et al. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. JAMA Oncology. 2025;11(10):1186–1193. doi:10.1001/jamaoncol.2025.2681 .
- Wang L, et al. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Network Open. 2024;7(7):e2421305. doi:10.1001/jamanetworkopen.2024.21305 .
- Watts EL, et al. Adiposity and cancer: systematic review and meta-analysis. Nature Metabolism. 2026;8(6):1426–1439. doi:10.1038/s42255-026-01542-8 .
- US Food and Drug Administration. Wegovy (semaglutide) prescribing information. View US label . Check current local information for other products and jurisdictions.
- ClinicalTrials.gov. FITWISE, NCT06518837 ; NCT07314528 ; PROSPECT, NCT07095517 .
.png)
.png)
.png)
.png)
Comments